Veru Overview
- Year Founded
-
1971
- Status
-
Public
- Employees
-
20
- Stock Symbol
-
VERU
- Investments
-
2
- Share Price
-
$1.94
- (As of Friday Closing)
Veru General Information
Description
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
Contact Information
Website
www.verupharma.comCorporate Office
- 2916 North Miami Avenue
- Suite 1000
- Miami, FL 33137
- United States
Corporate Office
- 2916 North Miami Avenue
- Suite 1000
- Miami, FL 33137
- United States
Veru Stock Performance
As of 20-Nov-2026, Veru’s stock price is $1.94. Its current market cap is $33.1M with 17.1M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.94 | $2.11 | $1.93 - $7.33 | $33.1M | 17.1M | 194K | -$0.58 |
Veru Financials Summary
As of 30-Jun-2026, Veru has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 30-Sep-2025 | FY 2024 30-Sep-2024 | FY 2023 30-Sep-2023 |
|---|---|---|---|---|
| EV | 22,306 | 43,915 | 97,095 | 63,149 |
| Revenue | 0 | 0 | 0 | 16,297 |
| EBITDA | (13,996) | (15,529) | (34,992) | (89,976) |
| Net Income | (13,609) | (22,726) | (37,801) | (93,153) |
| Total Assets | 37,028 | 29,836 | 60,419 | 50,023 |
| Total Debt | 2,683 | 3,117 | 13,519 | 14,405 |
Veru Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Veru Comparisons
Industry
Financing
Details
Veru Competitors (53)
One of Veru’s 53 competitors is Inovio Pharmaceuticals, a Corporation company based in Plymouth Meeting, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| Kura Oncology | Formerly VC-backed | San Diego, CA | ||||
| Seres Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Adicet Bio | Formerly VC-backed | Boston, MA | ||||
| Immunocore Holdings | Formerly VC-backed | Abingdon, United Kingdom |
Veru Patents
Veru Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260232637-A1 | Methods of treating peripheral and coronary artery disease | Pending | 12-Feb-2025 | ||
| WO-2026174088-A1 | Methods of treating peripheral and coronary artery disease | Pending | 12-Feb-2025 | ||
| WO-2026161240-A1 | Compositions comprising selective androgen receptor modulator compounds in combination with weight loss drugs | Pending | 26-Jan-2025 | ||
| US-20260137648-A1 | Compositions comprising selective androgen receptor modulator compounds in combination with weight loss drugs and uses thereof for incremental weight loss and management of adverse side effects of weight loss drugs on body composition | Pending | 03-Oct-2023 | ||
| US-12721830-B2 | Compositions comprising selective androgen receptor modulator compounds in combination with weight loss drugs and uses thereof for quality weight loss | Active | 03-Oct-2023 | A61K31/277 |
Veru Signals
Veru Investments & Acquisitions (2)
Veru’s most recent deal was a Corporate Asset Purchase with Camargo Pharmaceutical Services (Formulation rights for solifenacin). The deal was made on 11-Dec-2017.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Camargo Pharmaceutical Services (Formulation rights for solifenacin) | 11-Dec-2017 | Corporate Asset Purchase | Buildings and Property | ||
| Aspen Park Pharmaceuticals | 31-Oct-2016 | Merger/Acquisition | Therapeutic Devices |
Veru ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
38.67 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Veru FAQs
-
When was Veru founded?
Veru was founded in 1971.
-
Where is Veru headquartered?
Veru is headquartered in Miami, FL.
-
What is the size of Veru?
Veru has 20 total employees.
-
What industry is Veru in?
Veru’s primary industry is Drug Discovery.
-
Is Veru a private or public company?
Veru is a Public company.
-
What is Veru’s stock symbol?
The ticker symbol for Veru is VERU.
-
What is the current stock price of Veru?
As of 20-Nov-2026 the stock price of Veru is $1.94.
-
What is the current market cap of Veru?
The current market capitalization of Veru is $33.1M.
-
Who are Veru’s competitors?
Inovio Pharmaceuticals, Kura Oncology, Seres Therapeutics, Adicet Bio, and Immunocore Holdings are some of the 53 competitors of Veru.
-
What is Veru’s annual earnings per share (EPS)?
Veru’s EPS for 12 months was -$0.58.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process